AZN1N Stock Chart & Stats
$2964.41
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$2,710.26 - $3,700.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)120.00
Market Cap
$4.60T
Enterprise Value$249.25K
Total Cash (Recent Filing)$7.67B
Total Debt (Recent Filing)$33.92B
Price to Earnings (P/E)25.1
Beta0.32
Next Earnings
Jul 27, 2026EPS Estimate
43.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.74
Shares Outstanding1,551,024,500
10 Day Avg. Volume275
30 Day Avg. Volume120
Financial Highlights & Ratios
PEG Ratio0.58
Price to Book (P/B)5.91
Price to Sales (P/S)4.90
P/FCF Ratio33.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3,690.45Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
AstraZeneca News
AZN1N FAQ
What was AstraZeneca plc’s price range in the past 12 months?
AstraZeneca plc lowest stock price was $2710.26 and its highest was $3700.00 in the past 12 months.
What is AstraZeneca plc’s market cap?
AstraZeneca plc’s market cap is $4.60T.
When is AstraZeneca plc’s upcoming earnings report date?
AstraZeneca plc’s upcoming earnings report date is Jul 27, 2026 which is in 2 days.
How were AstraZeneca plc’s earnings last quarter?
AstraZeneca plc released its earnings results on Apr 29, 2026. The company reported $45.173 earnings per share for the quarter, beating the consensus estimate of $44.105 by $1.068.
Is AstraZeneca plc overvalued?
According to Wall Street analysts AstraZeneca plc’s price is currently Undervalued.
Does AstraZeneca plc pay dividends?
AstraZeneca plc does not currently pay dividends.
What is AstraZeneca plc’s EPS estimate?
AstraZeneca plc’s EPS estimate is 43.46.
How many shares outstanding does AstraZeneca plc have?
AstraZeneca plc has 1,551,024,500 shares outstanding.
What happened to AstraZeneca plc’s price movement after its last earnings report?
AstraZeneca plc reported an EPS of $45.173 in its last earnings report, beating expectations of $44.105. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of AstraZeneca plc?
Currently, no hedge funds are holding shares in MX:AZN1N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AstraZeneca Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3,690.45 (― Downside)
$3,690.45 (― Downside)
Blogger Sentiment
Neutral
MX:AZN1N Sentiment 50%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth $38.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
20.93%
12-Months-Change
Fundamentals
Return on Equity
1.89%
Trailing 12-Months
Asset Growth
5.03%
Trailing 12-Months
Company Description
AstraZeneca plc
AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas. In oncology, key marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. For cardiovascular, renal, and metabolism diseases, the company offers treatments such as Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR. Respiratory and immunology conditions are targeted by products like Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris. Additionally, rare diseases are treated with Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris. The company's product offerings also extend to Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for influenza; Seroquel IR/Seroquel XR for schizophrenia and bipolar disorder; Nexium and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for COVID-19. AstraZeneca serves primary and specialty care physicians globally, leveraging a network of distributors and local representative offices across the United Kingdom, the rest of Europe, the Americas, Asia, Africa, and Australasia. Strategic collaboration forms a vital component of its operations. Partnerships include an agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG for the development and commercialization of NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for transthyretin amyloidosis; Proteros Biostructures GmbH for the joint discovery of novel small molecules targeting hematological cancers; and Sierra Oncology, Inc. for the development and commercialization of AZD5153. Initially incorporated in 1992 as Zeneca Group PLC, the company adopted its current name, AstraZeneca PLC, in April 1999. It is headquartered in Cambridge, United Kingdom.
AZN1N Stock 12 Month Forecast
Average Price Target
$3,690.45